Clinical trials: Tumor Markers, Biological
Lung Adenocarcinoma
CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS
Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease.
- Trial name
- PAIR-LUNG (NCT07630246)
- Where
- 2 sites in Portugal
- Volunteers
- 140 people
- Sponsor
- Universidade Nova de Lisboa
Oral Squamous Cell Carcinoma
Developing an In-vitro Diagnostic Risk-Stratification Test for Oral Cancer
The purpose of this study is to verify the discriminatory value of previously identified salivary transcriptome and proteome markers for oral squamous cell cancer in an intended use population of patients with oral lesions…
- Trial name
- NCT01587573
- Testing
- saliva collection prior to clinically driven oral biopsy
- Where
- 5 sites in United States
- Volunteers
- 370 people
- Sponsor
- PeriRx
Oral Cancer
Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer
The goal of this observational study is to investigate the effectiveness of neoadjuvant chemoimmunotherapy (NACI) regimens in treating advanced oral squamous cell carcinoma (OSCC) patients.
- Trial name
- HNC-SYSU-005 (NCT06143761)
- Testing
- PD-1 inhibitor+carboplatin+albumin-bound paclitaxel
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Carcinoma, Hepatocellular
HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC
Early stage HCC is treated by curative surgical resection or by local ablation (such as radio-frequency) as the current standard of care.
- Trial name
- NCT03020342
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
To explore the non-inferiority of a cfDNA amplicon-based liquid biopsy technology vs. standard of care tissue biopsy-based NGS in detecting guideline- recommended biomarkers in patients with metastatic non-squamous Non-small Cell…
- Trial name
- LIQUIK (NCT04703153)
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Lucence Health Inc.
Breast Cancer
Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve
This is a multicentre, prospective study willing to evaluate AMH levels changes in response to chemotherapy plus GnRHa. In the present study we propose to determine AMH levels in breast cancer patients, aged <40yrs receiving…
- Trial name
- NCT02113553
- Testing
- Triptorelin
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Armando Santoro, MD
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Colorectal Cancer
Plasma Biomarkers C-RAC, ICORG 12-27, V1
This is an exploratory, translational, non-interventional and multi-centre clinical study.
- Trial name
- NCT02050737
- Where
- 14 sites in Ireland
- Volunteers
- 109 people
- Sponsor
- Cancer Trials Ireland
Metastatic Renal Cell Carcinoma
Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
The aim of this study is to identify and/or validate biomarkers and imaging markers to predict and monitor the activity of a new class of therapeutic agents called antiangiogenics for the treatment of metastatic renal cell…
- Trial name
- PREINSUT (NCT00930345)
- Testing
- Sunitinib (SUTENT)
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Prostate Cancer, Castration Resistant
PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.
- Conditions
- Advanced Prostate Cancer, Castration Resistant, Radium 223
- Trial name
- PRORADIUM (NCT02925702)
- Testing
- Radium 223 55mBq/Kg every 4 weeks intravenously
- Where
- 63 sites in Spain
- Volunteers
- 161 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Colon Cancer
Response to Immunotherapy in MMR-deficient Localized Colon Cancer
The aim of this study is to evaluate the safety and efficacy of neoadjuvant treatment with pembrolizumab before colonic resection in patients with early-stage (I-III) deficient mismatch repair (dMMR) colon cancer (CC).
- Trial name
- RESET-C (NCT05662527)
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Camilla Qvortrup
Pancreatic Tumor
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors
Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month.
- Trial name
- PACAomics (NCT01692873)
- Testing
- suspected pancreatic tumor
- Where
- France
- Volunteers
- 274 people
- Sponsor
- Institut Paoli-Calmettes
Patients With Suspected Prostate Cancer
Analysis of a New Biomarker for Prostate Cancer Diagnosis
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
- Trial name
- HEM (NCT01819740)
- Testing
- determine the levels of the "HEM" substance in seminal plasma
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli
Renal Cell Carcinoma
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
In this study, the investigators profiled plasma glycosaminoglycans (GAGs) in a retrospective consecutive series of patients with a radiographic finding of renal mass referred to primary surgery for renal cell carcinoma (RCC).
- Trial name
- NCT03471897
- Testing
- Glycosaminoglycan plasma score
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Chalmers University of Technology
Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation
French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer…
- Conditions
- Carcinoma, Non-Small-Cell Lung, ALK Gene Mutation, KRAS Gene Mutation, BRAF Gene Mutation
- Trial name
- NCT01700582
- Where
- 133 sites in France
- Volunteers
- 17,664 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Bladder Cancer
Aschistosoma Haematobiumspecific microRNAas a Tumor Marker for Early Diagnosis and Prognosis of Bilharzial Bladder Cancer in Eygpt
miRNAs have been detected in different bodily fluids, which suggests significant potential, such as their use as biomarkers in diagnostics and prognostics.
- Trial name
- NCT05697224
- Testing
- urinary micro RNA detection
- Volunteers
- 50 people
- Sponsor
- Sohag University
Cancer Therapy-related Cardiovascular Toxicity, Childhood Cancer
Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies
The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography…
- Conditions
- Cancer Therapy-related Cardiovascular Toxicity, Childhood Cancer, Chemotherapeutic Toxicity, Radiotherapy Side Effect
- Trial name
- CTRCT-pedia (NCT07408362)
- Testing
- Ergospirometry
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Liege
Breast Cancer
Feasibility Study of Biomarkers of Response to Neoadjuvant Paclitaxel in Locally Advanced Breast Cancer
The purpose of this study is to determine if the investigators are able to locate and measure certain characteristics in breast cancer tumors that have been treated with paclitaxel that may correlate to how well the cancer will…
- Trial name
- NCT01263613
- Testing
- tumor biopsy and blood draw
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Cancer, Head and Neck Cancer
Creation of the BioBank, Early Detection and Discovery Biomarkers
To establish a multidisciplinary research structure for tissue repository that facilitates projects that bridge specialties that normally may or may not interact.
- Conditions
- Pancreatic Cancer, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT00901680
- Where
- United States
- Volunteers
- 3,028 people, healthy volunteers welcome
- Sponsor
- Corewell Health East
Metastatic Colorectal Cancer
PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer
The primary objective of the two phase PERMAD trial is the evaluation of the impact of a personalized marker-driven treatment approach with early detection of progression and modification of treatment on cytokines and angiogenic…
- Trial name
- PERMAD (NCT02331927)
- Testing
- Aflibercept
- Where
- 3 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Ulm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.